Horvatić Herceg et al., 2006 - Google Patents

Urokinase-type plasminogen activator and its inhibitor in thyroid neoplasms: a cytosol study

Horvatić Herceg et al., 2006

Document ID: 3670367635859281167
Author: Horvatić Herceg G; Herceg D; Kralik M; Bence-Žigman Z; Tomić-Brzac H; Kulić A
Publication year: 2006
Publication venue: Wiener Klinische Wochenschrift

External Links

Cited by

Snippet

PURPOSE: Higher levels of urokinase-type plasminogen activator (uPA) and its inhibitor (PAI-1) are linked to the poor prognosis in a variety of malignances. uPA and PAI-1 were expressed in most thyroid carcinomas, as had been measured immunohistochemically …

Continue reading at www.academia.edu (PDF) (other versions)

102000003990 Urokinase-type plasminogen activator 0 title abstract description 36

Classifications

- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
- G01N33/574—Immunoassay; Biospecific binding assay for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57415—Specifically defined cancers of breast
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
- G01N33/573—Immunoassay; Biospecific binding assay for enzymes or isoenzymes
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
- G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
- G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
- G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
- G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/475—Assays involving growth factors
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment; Prognosis
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value

Similar Documents

Publication	Publication Date	Title
Honma et al.	2008	Clinical importance of estrogen receptor-β evaluation in breast cancer patients treated with adjuvant tamoxifen therapy
Yu et al.	1995	Prostate-specific antigen is a new favorable prognostic indicator for women with breast cancer
Bajetta et al.	1999	Chromogranin A, neuron specific enolase, carcinoembryonic antigen, and hydroxyindole acetic acid evaluation in patients with neuroendocrine tumors
Seetoo et al.	2003	Quantitative expression of protein markers of plasminogen activation system in prognosis of colorectal cancer
Bonk et al.	2019	Prognostic and diagnostic role of PSA immunohistochemistry: A tissue microarray study on 21,000 normal and cancerous tissues
Rowlands et al.	2012	Circulating insulin-like growth factors and IGF-binding proteins in PSA-detected prostate cancer: the large case–control study ProtecT
Hvamstad et al.	2003	Neuroendocrine serum tumour markers in hormone-resistant prostate cancer
Kotepui et al.	2016	Differential expression of matrix metalloproteinase-13 in association with invasion of breast cancer
Martins et al.	2009	Prognostic relevance of TTF-1 and MMP-9 expression in advanced lung adenocarcinoma
Shiba et al.	2016	Pancreatic neuroendocrine tumors: a single-center 20-year experience with 100 patients
Horvatić Herceg et al.	2006	Urokinase-type plasminogen activator and its inhibitor in thyroid neoplasms: a cytosol study
Wan et al.	2016	Elevated YKL-40 expression is associated with a poor prognosis in breast cancer patients
Paek et al.	2011	Prognostic significance of human epididymis protein 4 in epithelial ovarian cancer
Wu et al.	1998	Serum chromogranin A: early detection of hormonal resistance in prostate cancer patients
Sauter et al.	2004	Prostate-specific antigen expression in nipple aspirate fluid is associated with advanced breast cancer
Hasui et al.	1994	The content of urokinase-type plasminogen activator and tumor recurrence in superficial bladder cancer
Meng et al.	2019	Age, height, BMI and FBG predict prostate volume in ageing benign prostatic hyperplasia: Evidence from 5285 patients
Wahal et al.	2015	Lymphatic vessel assessment by podoplanin (D2-40) immunohistochemistry in breast cancer
Sagnak et al.	2011	Prognostic significance of neuroendocrine differentiation in prostate adenocarcinoma
US20180164318A1 (en)	2018-06-14	Methods, kits, and systems for treatment of metastatic papillary thyroid cancer
Hernandez et al.	2021	BRAFV600E, hypothyroidism, and human relaxin in thyroid carcinogenesis
Khan et al.	2016	Risk factors associated with thyroid carcinoma in North Pakistan
Ayadi et al.	2010	Correlation between immunohistochemical biomarkers expression and prognosis of ovarian carcinomas in Tunisian patients
Dorn et al.	2015	Assessment of kallikrein-related peptidase 5 (KLK5) protein expression in tumor tissue of advanced ovarian cancer patients by immunohistochemistry and ELISA: correlation with clinical outcome
Volm et al.	1999	Relationship of urokinase and urokinase receptor in non-small cell lung cancer to proliferation, angiogenesis, metastasis and patient survival.